CYP2D6 polymorphisms influence tamoxifen treatment outcomes in

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes

Frontiers Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis - ScienceDirect

Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

Role of CYP2D6 and other CYP enzymes in the metabolism of tamoxifen to

Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives - ScienceDirect

Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer, Egyptian Journal of Medical Human Genetics

Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients - Lim - 2011 - British Journal of Clinical Pharmacology - Wiley Online Library

Frontiers Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites